Dr Han on the Investigation of Neoadjuvant Therapy Plus a Dendritic Cell Vaccine in HER2+ Breast Cancer

Heather Han, MD, discusses initial safety and efficacy results from the phase 2 NATASHA trial in patients with early-stage HER2-positive breast cancer.

Related Keywords

,Heather Han ,Department Of Breast Oncology ,Moffitt Cancer Center ,Breast Oncology ,D ,Nct05501886 ,Phase 1 2 Natasha Trial Nct05325632 ,Early Stage Her2 Positive Breast Cancer ,